Frequency distribution of cytochrome p450 3a4 gene polymorphism in ethnic populations and in transplant recipients

Research Communications in Molecular Pathology and Pharmacology

Volumn 119, Issue 1-6, 2006, Pages 89-104

  Zhou, Xinchun ^a   Barber, W Henry ^a   Moore, Charles K ^a   Tee, Lee Y ^a   Aru, Giorgio ^a   Harrison, Sebron ^a   Mangilog, Brenda ^a   McDaniel, D Olga ^a,b  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

Author keywords

African Americans (AFAM); Caucasians (CAU); CYP 3A4; Frequency distribution; Genotype; Heterozygous; Homozygous; Polymorphism; Rejection; Transplantation

Indexed keywords

CYTOCHROME P450 3A4; IMMUNOSUPPRESSIVE AGENT;

AFRICAN AMERICAN; ARTICLE; BREAST CANCER; CAUCASIAN; DIABETES MELLITUS; DRUG METABOLISM; ETHNIC GROUP; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; GRAFT RECIPIENT; GRAFT REJECTION; HEART TRANSPLANTATION; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; HUMAN TISSUE; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTENSION; KIDNEY TRANSPLANTATION; LEUKEMIA; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSTATE CANCER; SEX RATIO; STATISTICAL ANALYSIS;

AFRICAN AMERICANS; ALLELES; CYTOCHROME P-450 ENZYME SYSTEM; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENE FREQUENCY; GRAFT REJECTION; HEART TRANSPLANTATION; HETEROZYGOTE; HOMOZYGOTE; HUMANS; KIDNEY TRANSPLANTATION; MALE; POLYMORPHISM, GENETIC; SEX FACTORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 35348894911     PISSN: 10780297     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Amirimani, B., Ning, B., Deitz, A.C., Weber, B.L., Kadlubar, F.F., Rebbeck, T.R. (2003) Increased transcriptional activity of the CYP3A4*1B promoter variant, Environ. Mol. Mutagen. 42:299-305.
2. Backman, J.T., Kivisto, K.T., Olkkola, K.T., Neuvonen, P.J. (1998) The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin, Eur. J. Clin. Pharmacol. 54:53-58.
3. Bertz, R.J., Granneman, G.R. (1997) Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokenetic interaction, Clin. Pharmacokinet. 32:210-258.
4. Blin, N., Stafford, D.W. (1976) A general method for isolation of high molecular weight DNA from eukaryotes, Nucleic Acids Res. 3:2303-2308.
5. Chenhsu, R.Y., Loong, C.C., Chou, M.H., Lin, M.F., Yang, W.C. (2000) Renal Allograft dysfunction associated with Rifampin-Tacrolimus interaction, Ann. Pharmacother. 34:27-30.
6. Cholerton, S., Daly, A.K., Idle, J.R. (1992) The role of individual human Cytochrome P-450 in drug metabolism and clinical response, Trends Pharmacol. Sci. 13:434-439.
7. Felix, C.A., Walker, A.H., Lange, B.J., Williams, T.M., Winick, N.J., Cheung, N.K.V., Lovett, B.D., Nowell, P.C., Blair, I.A., Rebbeck, T.R. (1998) Association of CYP3A4 genotype with treatment-related Leukemia, Proc. Natl. Acad. Sci. USA 95:13176-13181.
8. Galant, C., Gala, J.L., Berg, V.D., Berliere, M., Haumont, E., Horsmans, Y. (2001) Immunolocalisation of Cytochrome P-450 3A enzymes in human breast carcinoma: relationship with tumor differentiation and Steroid receptors, Pharmacol. Toxicol. 88: 142-146.
9. Gellner, K., Eiselt, R., Hustert, E., Arnold, H., Koch, I., Haberl, M., Deglmann, C.J., Burk, O., Buntefuss, D., Escher, S., Bishop, C., Koebe, H.G., Brinkmann, U., Klenk, H.P., Kleine, K., Meyer, U.A., Wojnowski, L. (2001) Genomic organization of the human CYP3A locus: identification of a new, inducible CYP3A gene, Pharmacogenetics 11:111-121.
10. Hesselink, D.A., van Schaik, R.H., van der Heiden, I.P., van der Werf, M., Gregoor, P.J., Lindemans, J., Weimar, W., van Gelder, T. (2003) Genetic polymorphisms of the CYP 3A4, CYP 3A5 and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus, Clin. Pharmacol Ther. 74:245-254.
11. Kadlubar, F.K., Berkowitz, G.S., Delongchamp, R.R., Wang, C., Green, B.L., Tang, G., Lamba, J., Schuetz, E., Wolff, M.S. (2003) The CYP 3A4* 1B variant is related to the onset of puberty, a known risk factor for the development of breast cancer, Cancer Epidemiol. Biomarkers Prev. 12: 327-331.
12. Kajinami, K., Brousseau, M.E., Ordovas, J.M., Schaefer, E.J. (2004) Cyp3A4 Genotypes and Plasma lipoprotein levels before and after treatment with atorvastatin in primary hypercholesterolemia, Am. J. cardiol. 93: 104-107.
13. Kittles, R.A., Chen, W., Panguluri, R.K., Ahaghotu, C., Jackson, A., Adebamowo, C.A., Griffin, R., Williams, T., Ukoli, F., Adams-Campbell, L., Kwagyan, J., Isaacs, W., Freeman, V., Dunston, G.M. (2002) CYP3A4-V and prostate cancer in African Americans: casual or confounding association because of population stratification, Hum. Genet. 110:553-560.
14. Koch, I., Weil, R., Wolbold, R., Brockmoller, J., Hustert, E., Burk, O., Nuessler, A., Neuhaus, P., Eichelbaum, M., Zanger, U., Wojnowski, L. (2002) Interindividual variability and tissue-specificity in the expression of cytochrome P450 3A mRNA, Drug Metab. Dispos. 30:1108-1114.
15. Kuehl, P., Zhang, J., Lin, Y., Lamba, J., Assem, M., Schuetz, J., Watkins, P.B., Daly, A., Wrighton, S.A., Hall, S.D., Maurel, P., Relling, M., Brimer, C., Yasuda, K., Venkataramanan, R., Strom, S., Thummel, K., Boguski, M.S., Schuetz, E. (2001) Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression, Nat. Genet. 27:383-391.
16. Lai, J., Vesprini, D., Chu, W., Jernstrom, H., Narod, S.A. (2001) CYP gene polymorphisms and early menarche, Mol. Genet. Metab. 74: 449-457.
17. Lamba, J.K., Lin, Y.S., Thummel, K., Daly, A., Watkins, P.B., Strom, S., Zhang, J., Schuetz, E.G. (2002) Common allelic variants in cytochrome P450 3A4 and their prevalence in different populations, Pharmacogenetics 12:121-132.
18. Lown, K.S., Kolars, J.C., Thummel, K.E., Barnett, J.L., Kunze, K.L., Wrighton, S.A., Watkins, P.B. (1994) Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Lack of prediction of the erythromycin breath test, Drug Metab. Dispos. 22: 947-955.
19. Min, D.I., Ellingrod, V.L. (2003) Association of the CYP3A4*1B5- flanking region polymorphis with cyclosporine pharmacokinetics in healthy subjects, Ther. Drug Monit. 25:305-309.
20. Matsumura, K. Saito, T., Takahashi, Y., Ozeki, T., Kiyotani, K., Fujieda, M., Yamazaki, H., Kunitoh, H., Kamataki, T. (2004) Identification of novel polymorphic enhancer of the human CYP3A4 gene, Mol. Pharmacol. 65: 326-334.
21. Neylan, J.F. (1998) Racial differences in renal transplantation after immunosuppression with tacrolimus versus cyclosporine, Transplantation 65:515-523.
22. Özdemir, V., Kalowa, W., Tang, B.K., Paterson, A.D., Walker, S.E., Endrenyi, L., Kashuba, A.D. (2000) Evaluation of the genetic component of variability in CYP 3A4 activity: a repeated drug administration method, Pharmacogenetics 10:373-388.
23. Paris, P.L., Kupelian, P.A., Hall, J.M., Williams, T.L., Levin, H., Klein, E.A., Casey, G., Witte, J.S. (1999) Association between a CYP3A4 genetic variant and clinical presentation in African-American prostate cancer patients, Cancer Epidemiol. Biomarkers Prev. 8:901-905.
24. Pichard, L., Fabre, I., Daujat, M., Domergue, J., Joyeux, H., Manurel, P. (1992) Effect of corticosteroids on the expression of cytochromes P450 and on cyclosporine A oxidase activity in primary cultures of human hepatocytes, Mol. Pharmacol. 41:1047-1055.
25. Rebbeck, T.R., Jaffe, J.M., Walker, A.H., Wein, A.J., Malkowicz, S.B. (1998) Modification of clinical presentation of prostate tumors by novel genetic variant in CYP3A4, J. Natl. Cancer Inst. 90:1225-1229.
26. Rendic, S., DiCarlo, F.J. (1997) Human cytochrome P-450 enzymes: a status report summarizing their reactions, substrates, inducers and inhibitors, Drug Metab. Rev. 29: 413-580.
27. Sata, F., Sapone, A., Elizondo, G., Stocker, P., Miller, V.P., Zheng, W., Raunio, H., Crespi, C.L., Gonzalez, F.J. (2000) CYP 3A4 llalic variants with amino acid substiutions in exons 7 and 12: Evidence for an allelic variant with altered cataytic activity, Clin. Pharmacol. Ther. 67: 48-56.
28. Shimada, T., Yamazake, H., Mimura, M., Inui, Y., Guengerich, F.P. (1994) Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians, J. Pharmacol. Exp. Ther 270:414-423.
29. Shinderman, M., Maxwell, S., Brawand-Amey, M., Golay, K.P., Baumann, P., Eap, C.B. (2003) Cytochrome P4503A4 metabolic activity, methadone blood concentrations, and methadone doses, Drug Alcohol Depend. 69:205-211.
30. Sprudle, A.B., Goodwin, B., Hodgson, E., Hopper, J.L., Chen, X., Purdie, D.M., McCredie, M.R., Giles, G.G., Chenevix-Trench, G., Liddle, C. (2002) The CYP34*1B polymorphism has no functional significance and is not associated with risk of breast or ovarian cancer, Pharmacogenetics 12:355-366.
31. Tayeb, M.T., Clark, C., Ameyaw, M.M., Haites, N.E., Evans, D.A., Tariq, M., Mobarek, A., Ofori-Adjei, D., McLeod, H.L. (2000) CYP3A4 promoter variant in Saudi, Ghanaian and Scottish Caucasian populations, Pharmacogenetics 10:753-756.
32. Thummel, K.E., Wilkinson, G.R. (1998) In vitro and in vivo drug interactions involving human CYP 3A, Annu. Rev. Pharmacol. Toxicol. 38: 389-430.
33. Walker, A.H., Jaffe, J.M., Gunasegaram, S., Cumming, S.A., Huang, C.S., Chern, H.D., Olopade, O.I., Weber, B.L., Rebbeck, T.R. (1998) Characteristic of an allelic variant in the nifedipine-specific element of CYP3A4: ethnic distribution and implications for prostate cancer risk. Mutations in brief no. 191. Online, Hum. Mutat. 12: 289.
34. Watkins, P.B. (1992) Drug metabolism by cytochromes P450 in the liver and small bowel, Gastroenterol. Clin. North Am. 21:511-526.
35. Zeigler- Johnson, C.M., Walker, A.H., Mancke, B., Spangler, E., Jalloh, M., McBride, S., Deitz, A., Malkowicz, S.B., Ofori-Adjei, D., Gueye, S.M., Rebbeck, T.R. (2002) Ethnic differences in the frequency of Prostate cancer susceptibility alleles of SRD5A2 and CYP3A4, Hum. Hered. 54:13-21.